Saltar al contenido
Merck
Todas las fotos(1)

Key Documents

View All Documentation

SMB00958

Sigma-Aldrich

N-Desmethyl imatinib

≥95%

Sinónimos:

N-(4-Methyl-3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-4-(piperazin-1-ylmethyl)benzamide, N-Desmethylimatinib, N-[4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-4-(1-piperazinylmethyl)benzamide, CGP74588, Desmethyl Gleevec, Norimatinib

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C28H29N7O
Número de CAS:
404844-02-6
Peso molecular:
479.58
UNSPSC Code:
12352205
NACRES:
NA.77

biological source

synthetic

Quality Level

200

grade

research grade

assay

≥95%

form

solid

mol wt

479.58 g/mol

storage condition

(Tightly closed. Dry. Keep in a well -ventilated place. Keep locked up or in an area accessible only to qualified or authorized persons.)

technique(s)

HPLC: suitable

solubility

ethanol: 0.20 mg/mL
DMF: 16 mg/mL

storage temp.

2-8°C

InChI

1S/C28H29N7O/c1-20-4-9-24(17-26(20)34-28-31-12-10-25(33-28)23-3-2-11-30-18-23)32-27(36)22-7-5-21(6-8-22)19-35-15-13-29-14-16-35/h2-12,17-18,29H,13-16,19H2,1H3,(H,32,36)(H,31,33,34)

InChI key

BQQYXPHRXIZMDM-UHFFFAOYSA-N

General description

N-Desmethyl imatinib is a pharmacologically active metabolite of imatinib with long elimination half-life. Imatinib is metabolized to N-desmethyl imatinib by CYPs 3A4 and 2C8.

Application

Application: Metabolomics research

Other Notes

For additional information on our range of Biochemicals, please complete this form.

pictograms

Health hazard
GHS08

signalword

Danger

Hazard Classifications

Carc. 2 - Lact. - Muta. 2 - Repr. 1B

Storage Class

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

Si necesita más asistencia, póngase en contacto con Atención al cliente

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Hans-Peter Gschwind et al.
Drug metabolism and disposition: the biological fate of chemicals, 33(10), 1503-1512 (2005-07-12)
Imatinib mesylate (GLEEVEC, GLIVEC, formerly STI571) has demonstrated unprecedented efficacy as first-line therapy for treatment for all phases of chronic myelogenous leukemia and metastatic and unresectable malignant gastrointestinal stromal tumors. Disposition and biotransformation of imatinib were studied in four male
Muhammad Suleman Khan et al.
Xenobiotica; the fate of foreign compounds in biological systems, 46(3), 278-287 (2015-07-15)
1. Imatinib is metabolized to N-desmethyl imatinib by CYPs 3A4 and 2C8. The effect of CYP2C8*3 genotype on N-desmethyl imatinib formation was unknown. 2. We examined imatinib N-demethylation in human liver microsomes (HLMs) genotyped for CYP2C8*3, in CYP2C8*3/*3 pooled HLMs
Yuji Mukai et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 1137, 121928-121928 (2019-12-27)
Therapeutic drug monitoring is important in patients taking BCR-ABL and Bruton's tyrosine kinase inhibitors (TKIs). Some TKI active metabolites with long elimination half-lives, such as dihydrodiol ibrutinib (DHI), N-desmethyl imatinib (N-DI), and N-desmethyl ponatinib (N-DP), have been characterized, indicating that

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico